{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma+%28disorder%29&page=43", "query": { "condition": "Non-Hodgkin's Lymphoma (disorder)", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 2150, "total_pages": 215, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma+%28disorder%29&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma+%28disorder%29&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T23:36:05.248Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04756726", "title": "Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Lymphoma, Non-Hodgkin's" ], "interventions": [ { "name": "cemsidomide", "type": "DRUG" }, { "name": "Dexamethasone Oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "C4 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2021-04-27", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-10-17T23:36:05.248Z", "location_count": 13, "location_summary": "Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04756726" }, { "nct_id": "NCT06119685", "title": "IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NHL", "Multiple Myeloma", "Blood Cancer", "Refractory Non-Hodgkin Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Multiple Myeloma", "Relapsed Multiple Myeloma" ], "interventions": [ { "name": "IDP-023", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indapta Therapeutics, INC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2023-10-25", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-10-17T23:36:05.248Z", "location_count": 12, "location_summary": "Los Angeles, California • Lake Mary, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119685" }, { "nct_id": "NCT04288726", "title": "Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type", "Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "CD30.CAR-EBVST cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 27, "start_date": "2020-09-16", "completion_date": "2037-06-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-17T23:36:05.248Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04288726" }, { "nct_id": "NCT03311126", "title": "Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma", "Non-hodgkin Lymphoma", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2017-09-29", "completion_date": "2023-07-31", "has_results": true, "last_update_posted_date": "2024-10-24", "last_synced_at": "2026-10-17T23:36:05.248Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03311126" }, { "nct_id": "NCT02304458", "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Hodgkin Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Melanoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Rhabdomyosarcoma", "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Refractory Hodgkin Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Melanoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Rhabdomyosarcoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 140, "start_date": "2015-03-30", "completion_date": "2023-03-31", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-10-17T23:36:05.248Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02304458" }, { "nct_id": "NCT00361049", "title": "Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "graft versus host disease prophylaxis/therapy", "type": "BIOLOGICAL" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2004-09", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2010-11-05", "last_synced_at": "2026-10-17T23:36:05.248Z", "location_count": 8, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00361049" }, { "nct_id": "NCT00788684", "title": "Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD20-Positive Lymphoid Malignancies", "Chronic Lymphoid Leukemia", "Hematological Malignancies", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "ABT-263", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2009-07-21", "completion_date": "2025-02-07", "has_results": false, "last_update_posted_date": "2025-02-20", "last_synced_at": "2026-10-17T23:36:05.248Z", "location_count": 4, "location_summary": "Tucson, Arizona • Stanford, California • Cleveland, Ohio + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788684" }, { "nct_id": "NCT01829958", "title": "Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non Hodgkin Lymphoma (NHL)", "Diffuse Large B-cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "Geriatric Assessment", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 201, "start_date": "2013-04", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-17T23:36:05.248Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01829958" }, { "nct_id": "NCT04629430", "title": "Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Non Hodgkin Lymphoma", "Acute Lymphocytic Leukemia", "Hodgkin Lymphoma", "Hodgkin Disease", "Myelofibrosis", "Myelodysplastic Syndromes", "Myeloproliferative Neoplasm", "Sickle Cell Disease", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Pre-biotic foods/drinks", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-02-19", "completion_date": "2022-10-28", "has_results": false, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-10-17T23:36:05.248Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629430" }, { "nct_id": "NCT02875067", "title": "Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Hodgkin Lymphoma", "Relapsed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2016-08-29", "completion_date": "2017-10-02", "has_results": true, "last_update_posted_date": "2020-08-14", "last_synced_at": "2026-10-17T23:36:05.248Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02875067" } ] }